Q-omics provides the consensus-scored ZNF554 profile across patient tissues and cancer cell-line models. ZNF554 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF554 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, ZNF554 RNA expression shows 20,526 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LIHC, and UVM as cancer lineages where ZNF554 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF554 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF554 survival associations across molecular data types. ZNF554 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF554 RNA expression–survival associations across cancer types. High ZNF554 expression shows favorable associations in HNSC, UCEC, KIRC, PAAD, BLCA and THYM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF554 RNA expression.
This table summarizes ZNF554 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF554. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF554 shows lower tumor expression in THCA, HNSC and BRCA and higher tumor expression in LIHC, CHOL and COAD. The LIHC box plot shows higher ZNF554 RNA expression in tumor versus normal tissue (log2 FC = +0.651, t-test p < 0.001).
This table shows molecular features associated with ZNF554 in patient tissues and cancer cell lines. In patient samples, ZNF554 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF554 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
